<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605523</url>
  </required_header>
  <id_info>
    <org_study_id>168/18</org_study_id>
    <nct_id>NCT04605523</nct_id>
  </id_info>
  <brief_title>Neurofilament Light- Chain in Ataxia Telangiectasia</brief_title>
  <official_title>Neurofilament Light- Chain as Biomarker for Neurodegeneration in Ataxia Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ataxia telangiectasia (A-T) is a rare autosomal recessive neurodegenerative disorder&#xD;
      characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability,&#xD;
      and cancer susceptibility. Currently there are no curative therapy options. The clinical&#xD;
      presentation of the disease has a wide variety is linked to the proven mutation,&#xD;
      immunological status and residual ATM kinase activity. Apart from these prognostic markers,&#xD;
      hardly any biomarker to predict disease course is available. Aim of the present proposal is&#xD;
      to evaluate serum concentrations of neurofilament - light chain in the serum of whole blood&#xD;
      as biomarker of neurodegeneration prospectively. In addition to that, the investigators will&#xD;
      examine the evolution of neurofilament - light chain longitudinally by blood samples from our&#xD;
      biobank as well as the concentration of neurofilament - light chain in cerebrospinal fluid&#xD;
      (CSF) of affected A-T patients from our biobank.&#xD;
&#xD;
      As in other neurodegenerative disorders and ataxias, the investigators expect that&#xD;
      neurofilament- light chain levels are increased in the A-T cohort and correlated to the&#xD;
      neurological status of A-T patients evaluated by means of AT-score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A-T is a neurodegenerative disease with mutation in the ATM gene. The clinical presentation&#xD;
      is complex and affects many different organ systems. Typical findings are progressive&#xD;
      cerebellar ataxia, malnutrition, immunodeficiency, chromosomal instability and cancer&#xD;
      susceptibility. In addition, new disease entities such as hepatopathy, diabetes and&#xD;
      endocrinological alterations are coming to the force.&#xD;
&#xD;
      The severity of the disease is closely related to presence of residual kinase activity,&#xD;
      immunological status and specific mutations. However, the individual course of the disease is&#xD;
      hard to predict. There is an urgent need to find and define reliable biomarkers for disease&#xD;
      progression in order to estimate the prognosis of individual disease course. According the&#xD;
      classification of estimated disease severity, the most suitable therapy and support can be&#xD;
      organized.&#xD;
&#xD;
      In many other neurodegenerative disorders neurofilament- light chain has been reported to be&#xD;
      a sensitive and reproducable serum biomarker for disease progression, activity and monitoring&#xD;
      of therapy efficaciousness. Neurofilament proteins indicate neuroaxonal damage independent of&#xD;
      causal pathway, the advantage of neurofilaments as a biomarker of disease progression is that&#xD;
      levels rise upon neuroaxonal damage not only in CSF but also in blood. Therefore, they can be&#xD;
      used to monitor disease activity without invasive procedures.&#xD;
&#xD;
      The aim of the proposal is to measure and evaluate neurofilament-light chain as serum&#xD;
      biomarker of disease progression in A-T patients. Additionally, the investigators will&#xD;
      measure neurofilament-light chain in CSF from their human biobank and characterize the&#xD;
      individual evolution in the serum of whole blood taken from the biobank.&#xD;
&#xD;
      In the prospective part of the study, the investigators will correlate the levels of&#xD;
      neurofilament to A-T scores for neurological assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurofilament - light chain</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Increase of neurofilament between age groups: A: 3-6 years; B: 6- &lt;12 years ; C:12-18 years , D: &gt;18 years. Comparison of absolute levels neurofilament (pg/ml) between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute increase per year of neurofilament (pg/ml)</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Absolute increase per year of neurofilament (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of neurofilament with age</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Correlation of neurofilament with age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of neurofilament with A-T score</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Correlation of neurofilament with A-T score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Variability of levels of neurofilament within 12 months</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Variability of levels of neurofilament within 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Levels of neurofilament in cerebrospinal fluid (CSF)</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Levels of neurofilament in cerebrospinal fluid (CSF)</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of neurofilament between serum and CSF</measure>
    <time_frame>01 Feb 2020 - 31 Dec 2020</time_frame>
    <description>Correlation of neurofilament between serum and CSF</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ataxia Telangiectasia</condition>
  <arm_group>
    <arm_group_label>Patients with Ataxia Telangiectasia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood withdrawal</intervention_name>
    <description>Additional blood sample will be taken within blood collection as part of standard care</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Patients with Ataxia Telangiectasia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum of whole blood CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with clinically / and or genetically confirmed diagnosis of ataxia telangiectasia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Patients: aged ≥2 and 45 years&#xD;
&#xD;
          -  known A-T&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cranial trauma in the last 6 months&#xD;
&#xD;
          -  ongoing malignant disease&#xD;
&#xD;
          -  Chronic diseases or infections (e.g. HIV, Tbc)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Alcohol, substance or drug abuse&#xD;
&#xD;
          -  inability to capture extend and consequences of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children´s Hospital, Pediatric Pulmonology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Children´s Hospital, Ped. Pulmonology</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Zielen</investigator_full_name>
    <investigator_title>Head of Pediatric Pulmonology</investigator_title>
  </responsible_party>
  <keyword>Ataxia telangiectasia</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>biomarker</keyword>
  <keyword>disease progression</keyword>
  <keyword>CSF</keyword>
  <keyword>Neurofilament light chain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

